PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis.

[1]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[2]  A. Kenny,et al.  The short term effects of tamoxifen on bone turnover in older women. , 1995, The Journal of clinical endocrinology and metabolism.

[3]  B. Adams-Huet,et al.  Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial , 1995, Annals of Internal Medicine.

[4]  R. Recker,et al.  Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[6]  B. Lanske,et al.  Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death , 1995, Molecular and cellular biology.

[7]  S. Nagataki,et al.  Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[8]  J. Reginster,et al.  A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. , 1995, The American journal of medicine.

[9]  E. Siris,et al.  Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[10]  E. Siris,et al.  Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. , 1995, The Journal of clinical endocrinology and metabolism.

[11]  G. Segre,et al.  Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. , 1995, Endocrinology.

[12]  A. Klibanski,et al.  Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. , 1994, The New England journal of medicine.

[13]  J Glowacki,et al.  Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. , 1994, Genes & development.

[14]  J. Orloff,et al.  Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. , 1994, Endocrine reviews.

[15]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[16]  B. Riggs,et al.  Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women. , 1993, The Journal of clinical endocrinology and metabolism.

[17]  O. Tørring,et al.  Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  J. Nordenström,et al.  Bone mineral density in patients with chronic hypoparathyroidism. , 1993, The Journal of clinical endocrinology and metabolism.

[19]  Truls Østbye,et al.  An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. , 1993, The Journal of clinical investigation.

[20]  A. F. Stewart,et al.  Parathyroid hormone-related protein. Evidence for secretion of a novel mid-region fragment by three different cell types. , 1992, The Journal of biological chemistry.

[21]  G. Hendy,et al.  A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. , 1992, The Journal of clinical endocrinology and metabolism.

[22]  R. Lindsay,et al.  Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  J. Hock,et al.  Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  R. Lindsay,et al.  The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. , 1990, The Journal of clinical endocrinology and metabolism.

[25]  T. Martin,et al.  Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. , 1989, Endocrinology.

[26]  T. Clemens,et al.  Skeletal disease in primary hyperparathyroidism , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  M. Kleerekoper,et al.  Mild asymptomatic primary hyperparathyroidism is not a risk factor for vertebral fractures. , 1988, Annals of internal medicine.

[28]  A. F. Stewart,et al.  Humoral hypercalcemia of malignancy. , 1988, Annals of Internal Medicine.

[29]  L. Klenerman,et al.  ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSIS , 1976, The Lancet.

[30]  P. Astrup,et al.  The acid-base metabolism. A new approach. , 1960, Lancet.

[31]  A. F. Stewart,et al.  Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans. , 1996, The Journal of clinical endocrinology and metabolism.

[32]  S. Ljunghall,et al.  Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. , 1996, The Journal of clinical endocrinology and metabolism.

[33]  R. Marier,et al.  Comparison of the pharmacokinetics of parenteral parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in healthy young humans. , 1995, The Journal of clinical endocrinology and metabolism.